Human beta-defensin 3 inhibits cell wall biosynthesis in Staphylococci.
Human beta-defensin 3 (hBD3) is a highly charged (+11) cationic host defense peptide, produced by epithelial cells and neutrophils. hBD3 retains antimicrobial activity against a broad range of pathogens, including multiresistant Staphylococcus aureus, even under high-salt conditions. Whereas antimicrobial host defense peptides are assumed to act by permeabilizing cell membranes, the transcriptional response pattern of hBD3-treated staphylococcal cells resembled that of vancomycin-treated cells (V. Sass, U. Pag, A. Tossi, G. Bierbaum, and H. G. Sahl, Int. J. Med. Microbiol. 298:619-633, 2008) and suggested that inhibition of cell wall biosynthesis is a major component of the killing process. hBD3-treated cells, inspected by transmission electron microscopy, showed localized protrusions of cytoplasmic contents, and analysis of the intracellular pool of nucleotide-activated cell wall precursors demonstrated accumulation of the final soluble precursor, UDP-MurNAc-pentapeptide. Accumulation is typically induced by antibiotics that inhibit membrane-bound steps of cell wall biosynthesis and also demonstrates that hBD3 does not impair the biosynthetic capacity of cells and does not cause gross leakage of small cytoplasmic compounds. In in vitro assays of individual membrane-associated cell wall biosynthesis reactions (MraY, MurG, FemX, and penicillin-binding protein 2 [PBP2]), hBD3 inhibited those enzymes which use the bactoprenol-bound cell wall building block lipid II as a substrate; quantitative analysis suggested that hBD3 may stoichiometrically bind to lipid II. We report that binding of hBD3 to defined, lipid II-rich sites of cell wall biosynthesis may lead to perturbation of the biosynthesis machinery, resulting in localized lesions in the cell wall as demonstrated by electron microscopy. The lesions may then allow for osmotic rupture of cells when defensins are tested under low-salt conditions.
Sass
Vera
V
Institute of Medical Microbiology, Immunology and ParasitologyPharmaceutical Microbiology Section, University of Bonn,53105 Bonn, Germany.
Schneider
Tanja
T
Wilmes
Miriam
M
Körner
Christian
C
Tossi
Alessandro
A
Novikova
Natalia
N
Shamova
Olga
O
Sahl
Hans-Georg
HG
D002473:Cell Wall / Q000378:metabolism* / Q000648:ultrastructure; D003593:Cytoplasm / Q000737:chemistry; D006801:Humans; D046529:Microscopy, Electron, Transmission; D013211:Staphylococcus aureus / Q000276:immunology* / Q000648:ultrastructure; D014538:Uridine Diphosphate N-Acetylmuramic Acid / Q000031:analogs & derivatives / Q000032:analysis / Q000378:metabolism; D023083:beta-Defensins / Q000276:immunology*
C422950:DEFB103A protein, human; D014538:Uridine Diphosphate N-Acetylmuramic Acid; D023083:beta-Defensins; C069249:muramyl-NAc-(pentapeptide)pyrophosphoryl-undecaprenol; C002225:UDP-N-acetylmuramic acid pentapeptide
Eur J Biochem. 1999 Jan;259(1-2):360-9
9914515
Biopolymers. 2002;66(4):236-48
12491537
Adv Microb Physiol. 1995;37:135-75
8540420
BMC Genomics. 2009 Sep 14;10:429
19751498
Mol Microbiol. 1998 Oct;30(2):317-27
9791177
Antimicrob Agents Chemother. 2005 May;49(5):1727-32
15855488
J Biol Chem. 2001 Feb 23;276(8):5707-13
11085990
Nature. 2002 Jan 24;415(6870):389-95
11807545
J Biol Chem. 2006 Jul 21;281(29):19861-71
16720578
J Biol Chem. 1999 Mar 26;274(13):8405-10
10085071
Antimicrob Agents Chemother. 2009 Apr;53(4):1610-8
19164139
Comb Chem High Throughput Screen. 2005 May;8(3):209-17
15892623
Curr Opin Immunol. 1998 Feb;10(1):41-4
9523109
Mol Microbiol. 2003 Aug;49(3):807-21
12864861
Curr Protein Pept Sci. 2005 Feb;6(1):35-51
15638767
J Antimicrob Chemother. 2008 Feb;61(2):341-52
18174202
Trends Biotechnol. 1998 Feb;16(2):82-8
9487736
FEMS Microbiol Lett. 2002 Jan 2;206(1):9-18
11786250
Curr Opin Immunol. 2002 Feb;14(1):96-102
11790538
Antimicrob Agents Chemother. 2006 Oct;50(10):3424-34
17005825
Mol Microbiol. 2000 Mar;35(6):1518-29
10760151
Mol Microbiol. 2004 Jul;53(2):675-85
15228543
Biochem J. 2003 Sep 15;374(Pt 3):707-14
12795637
J Pept Sci. 2008 Apr;14(4):518-23
18085509
Cell Mol Life Sci. 2006 Feb;63(4):469-86
16416029
Cell Mol Life Sci. 2006 Jun;63(11):1294-313
16710608
Biopolymers. 1998;47(6):451-63
10333737
FEBS Lett. 2008 Jun 25;582(15):2299-302
18519036
FEMS Microbiol Lett. 2004 Feb 9;231(1):67-71
14769468
J Bacteriol. 1988 Jan;170(1):84-8
3335484
Int J Med Microbiol. 2008 Oct;298(7-8):619-33
18455476
Nat Rev Microbiol. 2006 Jul;4(7):529-36
16778838
J Bacteriol. 2006 Feb;188(3):1120-33
16428416
Microbiol Mol Biol Rev. 2005 Dec;69(4):585-607
16339737
Biopolymers. 2000;55(1):4-30
10931439
J Bacteriol. 1985 May;162(2):833-6
3921529
Mol Microbiol. 2008 Jun;68(5):1315-27
18430139
Trends Microbiol. 2000 Sep;8(9):402-10
10989307
Proc Natl Acad Sci U S A. 2000 May 9;97(10):5028-30
10805764
J Leukoc Biol. 2005 Apr;77(4):466-75
15582982
Nat Immunol. 2005 Jun;6(6):551-7
15908936
FEMS Microbiol Lett. 1989 Apr;49(2-3):223-7
2501145
Curr Pharm Des. 2002;8(9):743-61
11945169
FASEB J. 2006 Jan;20(1):35-42
16394265
J Biol Chem. 2002 Mar 8;277(10):8279-89
11741980
J Bacteriol. 1991 Jun;173(11):3425-31
2045364
J Bacteriol. 1988 May;170(5):2197-201
3283106